Form 4: Iovance Biotherapeutics Executive Frederick G. Vogt Reports Stock Transactions

Frederick G. Vogt, Interim CEO & General Counsel of Iovance Biotherapeutics, reported the vesting of restricted stock units and subsequent tax withholding.

Summary

• Frederick G. Vogt, the Interim CEO & General Counsel of Iovance Biotherapeutics, reported transactions involving the company's stock.
• On December 2, 2024, 10,417 restricted stock units (RSUs) vested, converting into common stock.
• A total of 4,426 shares were withheld by the company to cover tax obligations related to the vesting of the RSUs.
• After the tax withholding, Mr. Vogt beneficially owns 210,236 shares of Iovance Biotherapeutics common stock.
• The vesting of the RSUs did not involve any monetary transaction, with a price of $0 per share.
• The tax withholding was executed at a price of $9.07 per share.

Sentiment

Score: 7

Explanation: The document reflects routine executive compensation activity, which is neither positive nor negative for the company's overall performance. It is a neutral event.

Industry Context

This is a routine filing related to executive compensation and is common for publicly traded companies.

Comparison to Industry Standards

• Stock-based compensation, including RSUs, is a standard practice for executive compensation in the biotechnology industry.
• Tax withholding upon vesting of RSUs is a common procedure to cover the tax liabilities of the recipient.
• Form 4 filings are a standard requirement for company insiders to report their transactions in company stock.

Stakeholder Impact

• The transaction has a minor impact on shareholders as it is related to executive compensation and does not represent a significant change in the company's financial position.

Key Dates

Keywords

stock, restricted stock units, RSU, vesting, tax withholding, insider trading, IOVA, Iovance Biotherapeutics, Frederick G. Vogt